Role of the Vector Genome and Underlying Factor IX Mutation in Immune Responses to AAV Gene Therapy for Hemophilia B

Journal of Translational Medicine - United Kingdom
doi 10.1186/1479-5876-12-25
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Major Role of Local Immune Responses in Antibody Formation to Factor IX in AAV Gene Transfer

Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2005English

Engineered Factor VII, Factor IX, and Factor X Variants for Hemophilia Gene Therapy

Journal of Genetic Syndromes & Gene Therapy
2012English

244. Factor VIII Immunogenicity Is a Barrier to AAV Gene Therapy for Hemophilia A

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2015English

823. Factor IX Expression in Skeletal Muscle of a Subject With Severe Hemophilia B Ten Years After AAV Gene Transfer

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2011English

AAV-mediated Gene Transfer for Hemophilia

Genetics in Medicine
MedicineGenetics
2002English

Immune Modulatory Cell Therapy for Hemophilia B Based on CD20-Targeted Lentiviral Gene Transfer to Primary B Cells

Molecular Therapy - Methods and Clinical Development
Molecular MedicineGeneticsMolecular Biology
2017English

Immune Responses to Gene Therapy Vectors: Influence on Vector Function and Effector Mechanisms

Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2004English

Anti-Cd20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor Mice

Frontiers in Immunology
AllergyImmunology
2014English

Molecular Basis of Hemophilia B: Identification of the Defect in Factor Ix Vancouver

1987English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy